In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.